Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 29;46(7):6675-6689.
doi: 10.3390/cimb46070398.

Potential New Inflammatory Markers in Bronchiectasis: A Literature Review

Francesco Rocco Bertuccio  1   2 , Nicola Baio  1   2 , Simone Montini  1   2 , Valentina Ferroni  1   2 , Vittorio Chino  3 , Lucrezia Pisanu  1   2 , Marianna Russo  1   2 , Ilaria Giana  1   2 , Alessandro Cascina  1   2 , Valentina Conio  1   2 , Amelia Grosso  2 , Erica Gini  2 , Federica Albicini  2 , Angelo Guido Corsico  1   2 , Giulia Maria Stella  1   2
Affiliations
Review

Potential New Inflammatory Markers in Bronchiectasis: A Literature Review

Francesco Rocco Bertuccio et al. Curr Issues Mol Biol. .

Abstract

Specific molecular and inflammatory endotypes have been identified for chronic respiratory disorders, including asthma and COPD (chronic obstructive pulmonary disease). These endotypes correspond with clinical aspects of disease, enabling targeted medicines to address certain pathophysiologic pathways, often referred to as "precision medicine". With respect to bronchiectasis, many comorbidities and underlying causes have been identified. Inflammatory endotypes have also been widely studied and reported. Additionally, several genes have been shown to affect disease progression. However, the lack of a clear classification has also hampered our understanding of the disease's natural course. The aim of this review is, thus, to summarize the current knowledge on biomarkers and actionable targets of this complex pathologic condition and to point out unmet needs, which are required in the design of effective diagnostic and therapeutic trials.

Keywords: TSLP; bronchiectasis; endotype; inflammatory molecular drivers; mucins; personalised medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
TSLP signalling.
Figure 2
Figure 2
TSLP receptor.
See this image and copyright information in PMC

References

    1. Chalmers J.D., Aliberti S., Blasi F. Management of Bronchiectasis in Adults. Eur. Respir. J. 2015;45:1446–1462. doi: 10.1183/09031936.00119114. - DOI - PubMed
    1. Lonni S., Chalmers J.D., Goeminne P.C., Mcdonnell M.J., Dimakou K., De Soyza A., Polverino E., Van de Kerkhove C., Rutherford R., Davison J., et al. Etiology of non–cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann. Am. Thorac. Soc. 2015;12:1764–1770. doi: 10.1513/AnnalsATS.201507-472OC. - DOI - PMC - PubMed
    1. Hill A.T., Sullivan A.L., Chalmers J.D., De Soyza A., Stuart Elborn J., Andres Floto R., Grillo L., Gruffydd-Jones K., Harvey A., Haworth C.S., et al. British Thoracic Society Guideline for Bronchiectasis in Adults. Thorax. 2019;74:1–69. doi: 10.1136/thoraxjnl-2018-212463. - DOI - PubMed
    1. Lim H.F., Tan N.S., Dehghan R., Shen M., Liew M.F., Bee S.W.L., Sia Y.Y., Liu J., Khor C.C., Kwok I., et al. Shortened Telomere Length in Sputum Cells of Bronchiectasis Patients is Associated with Dysfunctional Inflammatory Pathways. Lung. 2022;200:401–407. doi: 10.1007/s00408-022-00535-0. - DOI - PubMed
    1. McDonnell M.J., Aliberti S., Goeminne P.C., Restrepo M.I., Finch S., Pesci A., Dupont L.J., Fardon T.C., Wilson R., Loebinger M.R., et al. Comorbidities and the Risk of Mortality in Patients with Bronchiectasis: An International Multicentre Cohort Study. Lancet Respir. Med. 2016;4:969–979. doi: 10.1016/S2213-2600(16)30320-4. - DOI - PMC - PubMed

LinkOut - more resources